共 118 条
[1]
Thomas SHL(2016)Pharmacological treatment of acquired QT prolongation and torsades de pointes Br J Clin Pharmacol 81 420-427
[2]
Behr ER(2016)Predicting the unpredictable. Drug-induced QT prolongation and torsades de pointes J Am Coll Cardiol 67 1639-1650
[3]
Schwartz PJ(2017)Risk factors for QTc-prolongation: systematic review of the evidence Int J Clin Pharm 39 16-25
[4]
Woosley RL(2015)A detailed description and assessment of outcomes of patients with hospital recorded QTc prolongation Am J Cardiol 115 907-911
[5]
Vandael E(2010)Prevention of Torsade de Pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation Circulation 121 1047-1060
[6]
Vandenberk B(2016)High prevalence of risk factors in elderly patients using drugs associated with acquired torsades de pointes chronically in Colombia Br J Clin Pharmacol 82 504-511
[7]
Vandenberghe J(2003)Prescription of QT-prolonging drugs in a cohort of about 5 million outpatients Am J Med 114 135-141
[8]
Laksman Z(2014)Use of QT-prolonging medications in US emergency departments, 1995–2009 Pharmacoepidemiol Drug Saf 23 9-17
[9]
Momciu B(2004)Drug-induced prolongation of the QT interval N Engl J Med 350 1013-1022
[10]
Seong YW(2013)Development and validation of a risk score to predict QT interval prolongation in hospitalized patients Circ Cardiovasc Qual Outcomes 6 479-487